A dopamine D2 receptor agonist (Ki = 29 nM in a radioligand binding assay); selective for D2 over D1 dopamine receptors (Ki = >100,000 nM), as well as a panel of adrenergic, serotonin, benzodiazepine, and GABA receptors (IC50s = >9,000 nM); reduces spontaneous locomotor activity in mice at doses less than 50 mg/kg but increases it at a dose of 100 mg/kg; induces contralateral asymmetry in an open field test in 6-OHDA-lesioned mice; reverses locomotor deficits and restores interest in novel stimuli in a marmoset model of MPTP-induced Parkinson's disease